Day 1 of the 17th Asia-Pacific Prostate Cancer Conference 2016 (APCC) has commenced at the Melbourne Convention Centre (August 31 – September 3). Delegates will receive a Theranostics Australia informative insert in their APCC satchel packs, and those attending the event are encouraged to view our poster “Ga-68 PSMA PET CT in Rising PSA Post-Definitive Treatment” (CU 098). Theranostics Australia’s director & physician, A/Prof Nat Lenzo, will be presenting at the moderated poster session on Thursday, 5PM EST.
Private Theranostics Provider in Australia
We strive to develop and provide powerful innovative therapies
Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.
Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market.
For modern cancer treatment and a team of specialists who care about your wellbeing, contact us today.
Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms. Read More
Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission. Read More
Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer. Read More
Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue. Read More
Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient. Read More
Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers. Read More
|Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer||Lenzo N , Meyrick D and Turner J.||Diagnostics||2018 February|
|The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer||Meyrick D, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.||Nuclear Medicine Communications||2017 November|
Theranostics Australia is pleased to introduce Dr. Jerome Barley (Scientific Officer), Dr. Magdalena Wajrak (Chemist) and Sarah Ransom (Radiochemist Assistant) as the newest members of our team, bringing with them a multitude of experience, knowledge and talent.
Theranostics Australia’s Dr. Nat Lenzo recently presented at the WA Neuroendocrine Tumour Forum on August 3rd, hosted by the Western Australian Clinical Oncology Group (WACOG) and the Unicorn Foundation. The forum invited Neuroendocrine Tumour/Carcinoid (NET) patients, carers and interested health care workers to learn about the latest developments in the management of NETs.
His presentation can be found at http://theranostics.com.au/presentations/